NewsWorld
PredictionsDigestsScorecardTimelinesArticles
NewsWorld
HomePredictionsDigestsScorecardTimelinesArticlesWorldTechnologyPoliticsBusiness
AI-powered predictive news aggregation© 2026 NewsWorld. All rights reserved.
Trending
MilitaryIranNuclearTalksStrikesFebruaryDiplomaticIranianLimitedTargetsGenevaIssuesTensionsTimelineFacilitiesThursdayMissileDigestChinaRegionalTariffsPricesOccurBreakthrough
MilitaryIranNuclearTalksStrikesFebruaryDiplomaticIranianLimitedTargetsGenevaIssuesTensionsTimelineFacilitiesThursdayMissileDigestChinaRegionalTariffsPricesOccurBreakthrough
All Articles
STAT+: Xenon’s seizure drug study reads out soon. Here’s what to expect
STAT News
Published about 3 hours ago

STAT+: Xenon’s seizure drug study reads out soon. Here’s what to expect

STAT News · Feb 26, 2026 · Collected from RSS

Summary

Xenon Pharmaceuticals is developing a drug for the most common type of seizure experienced by people with epilepsy. Here's what to know.

Full Article

Plus: An appreciation for retiring Alkermes CEO Richard Pops Molly Ferguson/STAT Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. No more snow. Please. In this week’s newsletter, a preview of Xenon’s epilepsy study readout, the inside story of a rare disease drug that was FDA approvable until it wasn’t, and an appreciation for Richard Pops, the retiring CEO of Alkermes. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

Share this story
Read Original at STAT News

Related Articles

STAT Newsabout 2 hours ago
Questions on the agenda for ACIP’s next meeting

Casey Means faces off against Cassidy, a postponed vaccine advisory meeting, and more health news

STAT Newsabout 5 hours ago
Opinion: I tried to design a clinical trial for a supplement. 5 things got in the way

When Elise Felicione tried to design a clinical trial for a supplement, 5 things got in the way. It’s a lesson for the industry.

STAT Newsabout 5 hours ago
Brain implants: What’s standing in the way of pivotal trials, FDA approval

Thirty years after scientists demonstrated how brain implants can help rhesus monkeys move robotic limbs using only their mind, the clinical pathway for the technology is still a little out…

STAT Newsabout 5 hours ago
Opinion: I had a brother with schizophrenia. I can’t stop thinking about Nick Reiner’s siblings

When mental illness strikes a family, siblings are often overlooked.

STAT Newsabout 5 hours ago
STAT+: Rare disease advocates fume over FDA’s mixed signals

Families facing rare diseases feel whiplash over shifting and contradictory decisions by the FDA.

STAT Newsabout 14 hours ago
Trump administration pauses some Medicaid funding to Minnesota, citing fraud concerns

Vice President JD Vance announced Wednesday that the Trump administration would “temporarily halt” some Medicaid funding to the state of Minnesota over fraud concerns.